A few weeks later, Eisai – which takes the commercial lead on Leqembi – requested a reconsideration ... or two mutations in the apolipoprotein E4 (ApoE4) gene, which is a risk factor for ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla ... People who have a gene called APOE e4 are more likely to develop Alzheimer ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla)—that can ... People who have a gene called APOE e4 are more likely to develop Alzheimer’s than ...

The test could potentially help identify patients eligible for treatment with new amyloid-busting drugs like Eisai and Biogen’s Leqembi (lecanemab ... (APOE) E4 assay in human blood plasma ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab). Lecanemab was authorised by the MHRA for ...

Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease. KUOW is Seattle’s NPR news station. We are an ...

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

NPR's Jon Hamilton has been talking to people who've taken these drugs, and today he has the story of one of the first patients to receive the drug now marketed as Leqembi. JON HAMILTON ...